Jerri Hatch Joins Pacific Biomarkers as Associate Director, Business Development

SEATTLE, March 12 /PRNewswire-FirstCall/ -- Pacific Biomarkers, Inc. (PBI) (OTC Bulletin Board: PBMC), a provider of specialized central laboratory and contract research services, today announced that Jerri Hatch has joined the Company as Associate Director, Business Development.  The position reports to the Director of Business Development, Patrick Jackle.  

Ms. Hatch will be responsible for promoting PBI's scientific expertise and experience in biomarker services to pharmaceutical and biotechnology companies throughout the US.  She will emphasize PBI's capabilities in immunogenicity testing, cell-based assays, novel biomarker development, technology transfers, and cutting-edge technologies.  Prior to joining PBI, Ms. Hatch held biomarker service-related business development positions with Specialty Labs and Pathway Diagnostics.

Ron Helm, Chief Executive Officer of Pacific Biomarkers commented, "We are absolutely delighted that Jerri has joined PBI.  She has a stellar record of achievement in sales, consistently exceeding targets and winning multiple awards during her time at Specialty Labs and Pathway Diagnostics.  Jerri has extensive experience and knowledge of the pharmaceutical, healthcare and biotech industries, an important requirement for the successful marketing of PBI's laboratory services in support of clinical drug development.  We expect her to make a major contribution to our efforts in driving sales growth going forward."

"I'm thrilled that Jerri has agreed to accept this exciting opportunity at PBI," said Patrick Jackle, Director of Business Development.  "She has extensive sales and sales management experience and a history of implementing sales and marketing strategies that have differentiated her companies from the competition.  She brings to PBI the kind of energy and drive that should make a major contribution as we strengthen relationships with existing clients and seek to open new doors with our exciting clinical biomarker services."

Helm concluded, "We are very encouraged by our recent successes in signing significant new contracts for specialty testing in the areas of diabetes, cardiovascular disease, osteoporosis, and arthritis drug development, as well as by the rapid growth in demand for our clinical biomarker services, which focus on the emerging field of biomarker assay development and testing.  We believe PBI is building significant momentum as we move forward, and Jerri is joining us at just the right time to further advance our expanding business development efforts."

About Pacific Biomarkers, Inc. (PBI)

Established in 1989, PBI provides specialized central laboratory and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The Company provides expert services in the areas of cardiovascular disease, diabetes, osteoporosis, arthritis, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, New York State, and the Lipid Standardization Program. PBI's clients include many of the world's largest pharmaceutical, biotech, and diagnostic companies. PBI also provides clinical biomarker services focusing on the emerging field of biomarker assay development and testing. Services include validating and performing ligand-binding assays for novel clinical biomarkers, immunogenicity testing, cell based assay testing and multiplex testing.

PBI is headquartered in Seattle, Washington, and its common stock trades on the OTC Bulletin Board under the symbol "PBMC". For more information about PBI, visit the company's web site at www.pacbio.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This press release includes forward-looking statements including, but not limited to, the following:  results of business development activities; future growth; and the viability and acceptance of the Company's biomarker services.  These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ materially from those described in the forward-looking statements.  These risks include, but are not limited to, the following:  the Company's ability to enter into contracts for its laboratory testing or biomarker services; client changes or early terminations of studies; variability in backlog; the success of marketing and business development efforts, and competitive factors; the Company's ability to manage growth; and other risks and uncertainties set forth in periodic filings with the U.S. Securities and Exchange Commission (including Form 10-K for the year ended June 30, 2009).

SOURCE Pacific Biomarkers, Inc.